Ursodeoxycholic acid (UDCA) has been demonstrated to inhibit pathological neovascularization in the retina by downregulating the expression of inflammatory factors and normalizing the VEGF-STAT3 signaling axis, which aids in the treatment of retinopathy of prematurity (ROP) and diabetic retinopathy [114–116]. This evidence concerns the gene VEGFA and retinopathy of prematurity.